Rapport Therapeutics RAPP 深 沪
已收盘 10-16 16:00:00 美东时间
27.57
-2.000
-6.76%
华盛通- 最 高29.745
- 今 开29.50
- 成交量 41.22万股
- 最 低 26.925
- 昨 收 29.57
- 总市值 13.23亿
- 52周最高 52.93
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 23.75
- 委 比 0.00%
- 总股本 4797.83万
- 历史最高 52.93
- 量 比 1.56
- 振 幅 9.54%
- 历史最低 6.43
- 每 手 1
- 风险率 6.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rapport Therapeutics收跌6.76%，成交额1139.33万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
今天 05:40
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50
Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.
10-15 20:00
美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
10-06 20:02
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Rapport Therapeutics Inc (NASDAQ:RAPP) from $65 to $75. BTIG analyst Kambiz Y...
09-16 21:10
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
09-16 18:23
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics announced its management will participate in two upcoming investor events: the Cantor Global Healthcare Conference in New York City on September 9, 2026, and the TD Cowen Annual Neuropsychiatry Summit virtually on September 23, 2026. The company, focused on developing precision medicines for neurological and psychiatric disorders, uses its RAP technology platform to target specific brain regions. Its lead drug, RAP-219, is in...
09-02 11:00
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Rapport Therapeutics will host a virtual KOL event on September 22, 2026, featuring experts Mauricio Tohen, MD, and Gary Sachs, MD, to discuss challenges in treating bipolar mania, RAP-219's mechanism, and the ongoing Phase 2 trial with topline data expected in October 2026. RAP-219 is a TARPγ8-specific AMPA receptor NAM targeting bipolar mania and epilepsy, aiming to offer a differentiated treatment with precision targeting. The event will inclu...
08-24 11:00
